Pharma Focus Asia

Fusion Pharmaceuticals Acquisition by AstraZeneca Gets Shareholder Approval

Thursday, May 30, 2024

Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a company in the field of oncology focusing on the development of advanced radioconjugates (RCs) as targeted therapies, made an announcement today regarding the results of a special virtual meeting of its shareholders. At this meeting, shareholders voted in favor of a proposal related to a previously disclosed plan of arrangement with a wholly-owned subsidiary of AstraZeneca under the Canada Business Corporations Act. This arrangement involves AstraZeneca acquiring all outstanding shares of Fusion (referred to as the "Arrangement").

As of the record date of April 16, 2024, there were approximately 84,965,608 shares outstanding and eligible to vote. A total of 68,678,602 shares were voted at the meeting, representing roughly 80.83% of the total outstanding shares.

The Arrangement received approval, meeting the required affirmative vote percentages from both shareholders voting as a single class and shareholders excluding those whose votes are to be excluded under applicable regulations.

A detailed report on the voting outcomes for all matters discussed at the meeting will be filed on Fusion's profile on SEDAR+ at

Completion of the arrangement is subject to court approval and other customary closing conditions. Assuming these conditions are met, the transaction is expected to be finalized in the second quarter of 2024.



magazine-slider-imageCytiva - Supor Prime filtersMFA + MMA 20244th Annual Cleaning Validation 20242nd Annual Pharma Impurity Conclave 2024CPHI Korea 2024CHEMICAL INDONESIA 2024World Orphan Drug Congress Europe 2024INALAB 2024Thermo Fisher - Drug Discovery and the impact of mAbsAdvanced Therapies USA 2024ISPE Singapore Affiliate Conference & Exhibition 20242024 PDA Aseptic Manufacturing Excellence Conference2024 PDA Aseptic Processing of Biopharmaceuticals Conference